A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Healthy Participants
Latest Information Update: 22 Nov 2023
At a glance
- Drugs Rezpegaldesleukin (Primary)
- Indications Atopic dermatitis; Psoriasis; Systemic lupus erythematosus; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 21 Jul 2022 Status changed from active, no longer recruiting to completed.
- 07 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 03 Mar 2022 Planned End Date changed from 14 Jul 2022 to 25 Aug 2022.